Broadmark Equity Research Announces Investment Opinion On Questcor Pharmaceuticals; Broadmark Recommends QSC With a "Buy" Rating.Business Editors NOTE TO EDITORS: The following is an investment opinion issued by Broadmark Equity Research NEW YORK--(BUSINESS WIRE)--Aug. 20, 2002 Broadmark Equity Research, the research arm of Broadmark Capital, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control has initiated research coverage on Questcor Pharmaceuticals (AMEX AMEX See: American Stock Exchange : QSC QSC Quality Service Communications (Cologne, Germany) QSC Quilter Sound Company (QSC Audio Products Inc.) QSC Queens Surface Corporation QSC Low-Traffic Ship (radiotelegraphy) ) with a "Buy" rating and a short term price target of $2.32. The report is available through Broadmark and will be posted on Zacks and Multex. Questcor Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, acquisition and marketing of acute care and critical care hospitality/ specialty pharmaceutical products. The company has five products on the market in the US and markets a sixth product in Italy Italy (ĭt`əlē), Ital. Italia, officially Italian Republic, republic (2005 est. pop. 58,103,000), 116,303 sq mi (301,225 sq km), S Europe. through a strategic partner. Questcor is focusing on the US hospital market but has license agreements with numerous overseas partners to market its products worldwide. Questcor also has five products in various stages of development, from pre-clinical development Pre-clinical development is a stage in the development of a new drug that begins before clinical trials (testing in humans) can begin, and during which important safety and pharmacology data is collected. to a Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA trial. Companies currently covered by Broadmark include the following: Altarex Corporation (Toronto: AXO) Neutral AVANT Immunotherapeutics, Inc. (NasdaqNM:AVAN) Neutral Celsion Corporation (AMEX:CLN) Buy GTC Biotherapeutics, Inc. (NasdaqNM:GTCB) Buy InSite Vision Inc. (AMEX:ISV) Buy Ortec International Inc. (NasdaqSC:ORTC) Buy Questcor Pharmaceuticals (AMEX: QSC) Buy Ribozyme Pharma, Inc. (NasdaqNM:RZYM) Neutral Sheffield Pharma, Inc. (AMEX:SHM) Neutral To receive a copy of the QSC research report or for more information on Broadmark Equity Research, contact: Karl Kirwan Vice President-Research Healthcare Analyst Broadmark Capital, LLC www.broadmark.com 14 Penn Plaza 225 West 34th Street Suite 2006 New York, NY 10001 Office: (212) 714-9374 ext. 102 Fax: (212) 714-9376 |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion